Fatima Hajj
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fatima Hajj has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
Muhammad Shahid Mehmood
Institute of Microbiology, University of Agriculture Faisalabad, Faisalabad, Pakistan
13 shared publications- Erum Habib
Dow University of Health Sciences, Karachi, Pakistan
10 shared publications - Muhammad Usman Iqbal
Department of Medicine, King Edward Medical University, Lahore, Pakistan
8 shared publications - Inbsaat Iqbal
Department of Radiotherapy and Medical Oncology, King Edward Medical University, Lahore, Pakistan
3 shared publications Muhammad Usman Iqbal
Department of Surgery, King Edward Medical University, Lahore, Pakistan
3 shared publicationsAiema Hamid
Department of Surgery, Rawalpindi Medical University, Rawalpindi, Pakistan
2 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Protocols
Effectiveness of intraoperative supine repositioning strategies for preventing pressure injuries: a systematic review and meta-analysis protocol
Background: Pressure injuries are a common and preventable postoperative complication among adults undergoing surgery in the supine position. Although various intraoperative repositioning approaches, such as micromovement-based systems and curvilinear repositioning strategies, have been developed to redistribute pressure during surgery, current findings on their effectiveness have not been systematically evaluated. The purpose of this review is to explore the effects of these intraoperative supine repositioning strategies in adult surgical patients and to provide evidence to guide perioperative prevention practices through a meta-analysis of available randomized trials. Methods: A comprehensive literature search (from inception through November 2025) will be conducted in PubMed, Embase, Scopus, Web of Science, the Cochrane Library, and ClinicalTrials.gov to identify randomized controlled trials assessing intraoperative supine repositioning strategies. Additional studies will be retrieved through citation chaining and gray literature searches. We will use Rayyan for study selection and Review Manager (RevMan) for statistical analysis. Eligible studies will include adult surgical patients randomized to repositioning strategies compared with standard positioning or sham controls. The primary outcome will be the incidence of postoperative pressure injuries, while secondary outcomes will include satisfaction rates, changes in skin temperature, effects on interface pressures, and locations of pressure injuries. Results: This study aims to provide the first comprehensive synthesis of the effectiveness of intraoperative supine repositioning strategies for preventing pressure injuries. Findings are expected to clarify which repositioning approaches offer the greatest preventive benefit. Conclusion: Intraoperative supine repositioning strategies have the potential to reduce the development of pressure injuries among adult surgical patients. This systematic review and meta-analysis will synthesize current evidence to inform perioperative practice and guide the selection of optimal repositioning techniques for surgical pressure injury prevention.
- 3 November 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Protocols
Open AccessEffectiveness of intraoperative supine repositioning strategies for preventing pressure injuries: a systematic review and meta-analysis protocol
Background: Pressure injuries are a common and preventable postoperative complication among adults undergoing surgery in the supine position. Although various intraoperative repositioning approaches, such as micromovement-based systems and curvilinear repositioning strategies, have been developed to redistribute pressure during surgery, current findings on their effectiveness have not been systematically evaluated. The purpose of this review is to explore the effects of these intraoperative supine repositioning strategies in adult surgical patients and to provide evidence to guide perioperative prevention practices through a meta-analysis of available randomized trials. Methods: A comprehensive literature search (from inception through November 2025) will be conducted in PubMed, Embase, Scopus, Web of Science, the Cochrane Library, and ClinicalTrials.gov to identify randomized controlled trials assessing intraoperative supine repositioning strategies. Additional studies will be retrieved through citation chaining and gray literature searches. We will use Rayyan for study selection and Review Manager (RevMan) for statistical analysis. Eligible studies will include adult surgical patients randomized to repositioning strategies compared with standard positioning or sham controls. The primary outcome will be the incidence of postoperative pressure injuries, while secondary outcomes will include satisfaction rates, changes in skin temperature, effects on interface pressures, and locations of pressure injuries. Results: This study aims to provide the first comprehensive synthesis of the effectiveness of intraoperative supine repositioning strategies for preventing pressure injuries. Findings are expected to clarify which repositioning approaches offer the greatest preventive benefit. Conclusion: Intraoperative supine repositioning strategies have the potential to reduce the development of pressure injuries among adult surgical patients. This systematic review and meta-analysis will synthesize current evidence to inform perioperative practice and guide the selection of optimal repositioning techniques for surgical pressure injury prevention.
- Open Access
- 3 October 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Real-world effectiveness and safety of neoadjuvant pembrolizumab in early-stage triple-negative breast cancer: a systematic review and meta-analysis
- 3 October 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessReal-world effectiveness and safety of neoadjuvant pembrolizumab in early-stage triple-negative breast cancer: a systematic review and meta-analysis
- Open Access
- 15 July 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (8) , 5488-5493
Concurrent postpartum cerebral venous thrombosis and acute toxoplasmosis–debut of a unique clinical convergence: a case report
Introduction and importance: Cerebral venous thrombosis (CVT) is a rare but serious condition, with pregnancy and puerperium representing major risk factors. Toxoplasma gondii typically causes asymptomatic infection in immunocompetent individuals. No case of concurrent postpartum CVT and acute toxoplasmosis has previously been reported. Case presentation: A 27-year-old woman presented 14 days postpartum with headache, fever, altered sensorium, and left-sided weakness. Neurological examination revealed a Glasgow Coma Scale score of 8/15 with focal deficits. Serology demonstrated positive Toxoplasma gondii IgM antibodies, indicating a recent infection. MRI/MRV confirmed multiple venous infarcts with hemorrhagic transformation, consistent with CVT. Protein C and S levels were reduced; however, these were interpreted cautiously, as acute thrombosis, systemic inflammation, and puerperium can transiently lower natural anticoagulant levels. Repeat testing post-recovery was planned. The patient was managed with anticoagulation, corticosteroids, and supportive care, followed by oral rivaroxaban and physiotherapy, achieving significant neurological recovery over 2 months. Clinical discussion: The concurrence of postpartum CVT and positive Toxoplasma gondii serology is unprecedented. Pregnancy-related hypercoagulability, compounded by infection-induced endothelial dysfunction, likely contributed to thrombosis. Reduced Protein C and S levels, measured during acute thrombosis or puerperium, may not reflect inherited deficiency; repeat testing after anticoagulation completion is necessary before diagnosing congenital deficiency. Anticoagulation, per international guidelines, remained the cornerstone of management and proved effective despite hemorrhagic infarcts. Conclusion: This first documented case of postpartum CVT with concurrent Toxoplasma gondii serology suggestive of recent infection underscores the importance of prompt recognition and timely anticoagulation.
- 15 July 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (8) , 5488-5493
Open AccessConcurrent postpartum cerebral venous thrombosis and acute toxoplasmosis–debut of a unique clinical convergence: a case report
Introduction and importance: Cerebral venous thrombosis (CVT) is a rare but serious condition, with pregnancy and puerperium representing major risk factors. Toxoplasma gondii typically causes asymptomatic infection in immunocompetent individuals. No case of concurrent postpartum CVT and acute toxoplasmosis has previously been reported. Case presentation: A 27-year-old woman presented 14 days postpartum with headache, fever, altered sensorium, and left-sided weakness. Neurological examination revealed a Glasgow Coma Scale score of 8/15 with focal deficits. Serology demonstrated positive Toxoplasma gondii IgM antibodies, indicating a recent infection. MRI/MRV confirmed multiple venous infarcts with hemorrhagic transformation, consistent with CVT. Protein C and S levels were reduced; however, these were interpreted cautiously, as acute thrombosis, systemic inflammation, and puerperium can transiently lower natural anticoagulant levels. Repeat testing post-recovery was planned. The patient was managed with anticoagulation, corticosteroids, and supportive care, followed by oral rivaroxaban and physiotherapy, achieving significant neurological recovery over 2 months. Clinical discussion: The concurrence of postpartum CVT and positive Toxoplasma gondii serology is unprecedented. Pregnancy-related hypercoagulability, compounded by infection-induced endothelial dysfunction, likely contributed to thrombosis. Reduced Protein C and S levels, measured during acute thrombosis or puerperium, may not reflect inherited deficiency; repeat testing after anticoagulation completion is necessary before diagnosing congenital deficiency. Anticoagulation, per international guidelines, remained the cornerstone of management and proved effective despite hemorrhagic infarcts. Conclusion: This first documented case of postpartum CVT with concurrent Toxoplasma gondii serology suggestive of recent infection underscores the importance of prompt recognition and timely anticoagulation.
- Open Access
- 30 June 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (8) , 5524-5525
Pegcetacoplan as a targeted C3 inhibitor in C3 glomerulopathy and immune-complex MPGN
- 30 June 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (8) , 5524-5525
Open AccessPegcetacoplan as a targeted C3 inhibitor in C3 glomerulopathy and immune-complex MPGN
- Open Access
- 4 June 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Protocols
- Vol. 30 (3) , 38-43
Ginger as a low-cost option for postoperative nausea and vomiting prevention after laparoscopic surgery in low- and middle-income countries: a systematic review and meta-analysis protocol
Background: Postoperative nausea and vomiting (PONV) is a common complication following laparoscopic surgery and remains a significant source of patient discomfort and healthcare burden. Although pharmacologic prophylaxis is widely used, PONV incidence remains considerable, particularly in low- and middle-income countries (LMICs), where resource constraints may limit access to newer antiemetics. Ginger ( Zingiber officinale ), a widely available and inexpensive herbal remedy, has demonstrated potential antiemetic effects in clinical trials. However, evidence remains inconsistent, and no focused synthesis has evaluated its role specifically in laparoscopic procedures in LMICs. This protocol outlines a systematic review and meta-analysis to assess the efficacy and safety of ginger versus placebo for preventing PONV after laparoscopic surgery in LMICs. Methods: PubMed, Embase, Scopus, Web of Science, Cochrane Library, and ClinicalTrials.gov will be searched through February 2026 to identify randomized controlled trials comparing ginger with placebo in adults undergoing laparoscopic procedures in LMICs. Gray literature, including Google Scholar and citation tracking, will also be searched. Study selection, data extraction, and risk-of-bias assessment will be conducted independently by two reviewers using the Cochrane Risk of Bias 2 tool. Primary outcomes will include PONV incidence. Secondary outcomes will include nausea and vomiting severity, rescue antiemetic use, and adverse events. Random-effects meta-analysis will be performed using risk ratios or mean differences with 95% confidence intervals. Pre-specified subgroup and sensitivity analyses will be conducted, and evidence certainty will be assessed using GRADE. Results: This review aims to provide a focused synthesis of randomized evidence evaluating ginger for PONV prevention after laparoscopic surgery in LMICs. The findings are expected to clarify its comparative efficacy and safety profile relative to placebo. Conclusion: The findings of this systematic review and meta-analysis are expected to inform perioperative care strategies in resource-limited settings and clarify the potential role of ginger as a low-cost option for PONV prevention.
- 4 June 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Protocols
- Vol. 30 (3) , 38-43
Open AccessGinger as a low-cost option for postoperative nausea and vomiting prevention after laparoscopic surgery in low- and middle-income countries: a systematic review and meta-analysis protocol
Background: Postoperative nausea and vomiting (PONV) is a common complication following laparoscopic surgery and remains a significant source of patient discomfort and healthcare burden. Although pharmacologic prophylaxis is widely used, PONV incidence remains considerable, particularly in low- and middle-income countries (LMICs), where resource constraints may limit access to newer antiemetics. Ginger ( Zingiber officinale ), a widely available and inexpensive herbal remedy, has demonstrated potential antiemetic effects in clinical trials. However, evidence remains inconsistent, and no focused synthesis has evaluated its role specifically in laparoscopic procedures in LMICs. This protocol outlines a systematic review and meta-analysis to assess the efficacy and safety of ginger versus placebo for preventing PONV after laparoscopic surgery in LMICs. Methods: PubMed, Embase, Scopus, Web of Science, Cochrane Library, and ClinicalTrials.gov will be searched through February 2026 to identify randomized controlled trials comparing ginger with placebo in adults undergoing laparoscopic procedures in LMICs. Gray literature, including Google Scholar and citation tracking, will also be searched. Study selection, data extraction, and risk-of-bias assessment will be conducted independently by two reviewers using the Cochrane Risk of Bias 2 tool. Primary outcomes will include PONV incidence. Secondary outcomes will include nausea and vomiting severity, rescue antiemetic use, and adverse events. Random-effects meta-analysis will be performed using risk ratios or mean differences with 95% confidence intervals. Pre-specified subgroup and sensitivity analyses will be conducted, and evidence certainty will be assessed using GRADE. Results: This review aims to provide a focused synthesis of randomized evidence evaluating ginger for PONV prevention after laparoscopic surgery in LMICs. The findings are expected to clarify its comparative efficacy and safety profile relative to placebo. Conclusion: The findings of this systematic review and meta-analysis are expected to inform perioperative care strategies in resource-limited settings and clarify the potential role of ginger as a low-cost option for PONV prevention.
- Open Access
- 8 May 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3905-3906
AI-programmable therapeutics via metagenomic foundation models for rare phage-mediated autoimmune modulations: early translational risks and benefits
- 8 May 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3905-3906
Open AccessAI-programmable therapeutics via metagenomic foundation models for rare phage-mediated autoimmune modulations: early translational risks and benefits
- Open Access
Efficacy and Safety of Crovalimab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Meta‐Analysis
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life‐threatening disorder characterized by complement‐mediated hemolysis. Crovalimab, a novel anti‐C5 monoclonal antibody, may offer a more convenient alternative to current therapies, highlighting the need for a comprehensive analysis of its efficacy and safety. Methods: A comprehensive search was conducted through PubMed, Embase, Cochrane, and clinicaltrials.gov using relevant keywords from inception until January 2025. Statistical calculation was conducted using MetaXL 5.3 by employing a random effects model to estimate the pooled event rates with 95% CI. Heterogeneity was assessed using the I 2 and χ 2 statistics. Results: This meta‐analysis included four studies involving 275 patients with a mean age of 41.87 ± 13.34 years with rate of hemolysis control of 86% (95% CI: 77%–94%, I 2 = 73%) and transfusion avoidance in 77% of patients (95% CI: 56%–93%, I 2 = 90%), breakthrough hemolysis of 10% (95% CI: 6%–13%, I 2 = 0%) and hemoglobin stabilization in 69% patients (95% CI: 43%–90%, I 2 = 98%). The incidence rate of any adverse event was 89% (95% CI: 76%–98%, I 2 = 87%) and serious adverse events 15% (95% CI: 7%–25%, I 2 = 74%). Conclusion: We observed high rates of hemolysis control and transfusion avoidance but significant adverse events. Study heterogeneity and publication bias limit generalizability, highlighting the need for larger, more robust trials. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission
Open AccessEfficacy and Safety of Crovalimab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Meta‐Analysis
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life‐threatening disorder characterized by complement‐mediated hemolysis. Crovalimab, a novel anti‐C5 monoclonal antibody, may offer a more convenient alternative to current therapies, highlighting the need for a comprehensive analysis of its efficacy and safety. Methods: A comprehensive search was conducted through PubMed, Embase, Cochrane, and clinicaltrials.gov using relevant keywords from inception until January 2025. Statistical calculation was conducted using MetaXL 5.3 by employing a random effects model to estimate the pooled event rates with 95% CI. Heterogeneity was assessed using the I 2 and χ 2 statistics. Results: This meta‐analysis included four studies involving 275 patients with a mean age of 41.87 ± 13.34 years with rate of hemolysis control of 86% (95% CI: 77%–94%, I 2 = 73%) and transfusion avoidance in 77% of patients (95% CI: 56%–93%, I 2 = 90%), breakthrough hemolysis of 10% (95% CI: 6%–13%, I 2 = 0%) and hemoglobin stabilization in 69% patients (95% CI: 43%–90%, I 2 = 98%). The incidence rate of any adverse event was 89% (95% CI: 76%–98%, I 2 = 87%) and serious adverse events 15% (95% CI: 7%–25%, I 2 = 74%). Conclusion: We observed high rates of hemolysis control and transfusion avoidance but significant adverse events. Study heterogeneity and publication bias limit generalizability, highlighting the need for larger, more robust trials. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission
- Open Access
- 17 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3823-3824
TGIF1-mediated corneal fibrosis inhibition: a gene-editing alternative to keratoplasty?
- 17 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3823-3824
Open AccessTGIF1-mediated corneal fibrosis inhibition: a gene-editing alternative to keratoplasty?
- Open Access
- 6 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3821-3822
Impact of time-of-day on immunochemotherapy efficacy in non–small cell lung cancer
Non–small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases and remains a leading cause of cancer mortality worldwide. Pathophysiologically, NSCLC arises from genetic alterations such as EGFR, KRAS, and ALK mutations, which drive dysregulated signaling, uncontrolled proliferation, and immune evasion. Standard treatments include surgery, radiotherapy, platinum-based chemotherapy, and immunotherapy with PD-1/PD-L1 inhibitors, yet survival outcomes remain suboptimal. Emerging evidence suggests that circadian biology influences therapeutic efficacy, with time-of-day (ToD) immunochemotherapy offering a novel approach to optimize outcomes. Mechanistically, circadian rhythms regulate immune cell trafficking, cytokine release, and drug metabolism, thereby modulating treatment response and toxicity. Clinical trials in NSCLC demonstrate that early-day administration of immunochemotherapy improves progression-free and overall survival compared to late dosing. Similar chronotherapy benefits have been reported in colorectal, breast, pancreatic, and hepatocellular cancers, underscoring broad translational relevance. Despite promise, challenges include patient heterogeneity in circadian rhythms, logistical barriers in oncology clinics, and limited biomarker validation. Future strategies should prioritize multicenter validation, integration of chronobiological profiling, and exploration of combination therapies. Cost-effectiveness analyses, awareness campaigns, and clinical drives to evaluate safety and adherence will be essential to establish trust and optimize outcomes.
- 6 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3821-3822
Open AccessImpact of time-of-day on immunochemotherapy efficacy in non–small cell lung cancer
Non–small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases and remains a leading cause of cancer mortality worldwide. Pathophysiologically, NSCLC arises from genetic alterations such as EGFR, KRAS, and ALK mutations, which drive dysregulated signaling, uncontrolled proliferation, and immune evasion. Standard treatments include surgery, radiotherapy, platinum-based chemotherapy, and immunotherapy with PD-1/PD-L1 inhibitors, yet survival outcomes remain suboptimal. Emerging evidence suggests that circadian biology influences therapeutic efficacy, with time-of-day (ToD) immunochemotherapy offering a novel approach to optimize outcomes. Mechanistically, circadian rhythms regulate immune cell trafficking, cytokine release, and drug metabolism, thereby modulating treatment response and toxicity. Clinical trials in NSCLC demonstrate that early-day administration of immunochemotherapy improves progression-free and overall survival compared to late dosing. Similar chronotherapy benefits have been reported in colorectal, breast, pancreatic, and hepatocellular cancers, underscoring broad translational relevance. Despite promise, challenges include patient heterogeneity in circadian rhythms, logistical barriers in oncology clinics, and limited biomarker validation. Future strategies should prioritize multicenter validation, integration of chronobiological profiling, and exploration of combination therapies. Cost-effectiveness analyses, awareness campaigns, and clinical drives to evaluate safety and adherence will be essential to establish trust and optimize outcomes.
- Open Access
- 3 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3815-3816
Fungal intratumoral dysbiosis promoting PD-L1 expression in metastatic uveal melanoma with ocular inflammatory mimicry
- 3 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3815-3816
Open AccessFungal intratumoral dysbiosis promoting PD-L1 expression in metastatic uveal melanoma with ocular inflammatory mimicry